Sustained release formulations of rhVEGF<sub>165</sub> produce a durable response in a murine model of peripheral angiogenesis by Daugherty, A L et al.
        
Citation for published version:
Daugherty, AL, Rangell, LK, Eckert, R, Zavala-Solorio, J, Peale, F & Mrsny, RJ 2011, 'Sustained release
formulations of rhVEGF165 produce a durable response in a murine model of peripheral angiogenesis',
European Journal of Pharmaceutics and Biopharmaceutics, vol. 78, no. 2, pp. 289-297.
https://doi.org/10.1016/j.ejpb.2011.03.011
DOI:
10.1016/j.ejpb.2011.03.011
Publication date:
2011
Document Version
Peer reviewed version
Link to publication
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
Daugherty et al – Local sustained delivery of rhVEGF165 – revised version 
 
1 
 
Revised manuscript – March 1, 2011 
 
Sustained release formulations of rhVEGF165 produce a 
durable response in a murine model of peripheral 
angiogenesis 
 
Ann L Daugherty
1
, Linda K. Rangell
1
, Renee Eckert
1
, Jose Zavala-Solorio
1
, Frank Peale
1
, 
and Randall J. Mrsny
1
,
 2
 
 
Affiliations:  
1
Genentech, Inc. S. San Francisco, CA 94080 
2
current address: Department of Pharmacy and Pharmacology, University of Bath, 
Claverton Down, Bath BA2 7AY England 
 
 
KEYWORDS: angiogenesis, vascular endothelial growth factor, VEGF, PLGA 
microspheres, PLGA:NMP gels, vascular casts, peripheral vascular disease 
 
Daugherty et al – Local sustained delivery of rhVEGF165 – revised version 
 
2 
 
ABSTRACT 
Local delivery of therapeutic angiogenic agents that stimulate blood vessel formation 
represents a promising strategy for the treatment of peripheral vascular disease (PVD).  
At present, requirements for temporal and spatial parameters for localized delivery are 
unclear, with a variety of sustained delivery approaches being examined.  Two polymer-
based sustained formulations containing the 165 amino acid isoform of human 
recombinant Vascular Endothelial Growth Factor-A (rhVEGF165) were evaluated for their 
potential application in the treatment of PVD following intramuscular injection.  
Microspheres prepared from a 50:50 ratio of polylactic-co-glycolic acid (PLGA) and a 
gel of PLGA polymer solubilized in N-methyl pyrrolidone (PLGA:NMP) were each 
loaded with rhVEGF165 and tested in vitro and in vivo.  PLGA microspheres averaged 
~30 μm in diameter and contained 8.9% (w/w) rhVEGF165 while the PLGA:NMP gel was 
formulated with varying amounts of spray freeze dried rhVEGF165 to result in final gel 
formulations having concentrations of 0.36, 0.72, or 3.6 mg/mL rhVEGF165.  In vitro 
release of rhVEGF165 from PLGA microspheres showed ~10% cumulative release by day 
6 whereas the cumulative release of rhVEGF165 from the PLGA:NMP gel matrices 
(0.65% w/w loading) was less than 0.25% at this same time point.  While the in vitro 
release characteristics of these two sustained-release formulations were broadly different, 
the plasma rhVEGF165 concentration-time profiles following hind-limb intramuscular 
(IM) injection of these formulations in non-compromised rats revealed similar in vivo 
pharmacokinetics.  Three-dimensional resin casts of vascular architecture were prepared 
at days 3, 7, 14, 21, 28, 60 and 75 following a single IM dosing of these sustained release 
microsphere and gel matrix formulations in the gastrocnemius muscle of immune-
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compromised mice.  Scanning electron microscopic visualization of these vascular casts 
demonstrated spatial arrangement of capillary sprouts and vessel enlargement consistent 
with profound vascular changes occurring within three days of dosing that persisted for 
two months, approximately one month beyond the anticipated completion of rhVEGF165 
release from these sustained delivery formulations.  Vascular re-modeling events were 
correlated with histological and immunohistochemical parameters attributed to known 
biological actions of rhVEGF165 signaling.  Together, these pharmacokinetic and 
pharmacodynamic results support the use of sustained release PLGA-based formulations 
for the local delivery of rhVEGF165 to achieve a durable vascular re-modeling response.   
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INTRODUCTION 
 
Vascular endothelial growth factor (VEGF) is a potent angiogenic mitogen [1]. VEGF 
expression is up-regulated by hypoxia-inducible factor and functions to increase blood 
vessel diameter by stimulating nitric oxide synthetase, generating the vaso-active agent 
nitric oxide [2].  Acting through this mediator, VEGF increases vessel wall permeability, 
creating a pathway for proliferating and migrating endothelial cells to establish nascent 
blood vessels, as well as inducing local vascular hypotension.  VEGF has also been 
shown to be a pleuripotent cytokine capable of not only inducing endothelial responses 
but also of recruiting cells such as monocytes that secrete a plethora of additional 
complementary growth factors [3].  Such potent actions resulting in neovascularization 
make VEGF a promising therapeutic candidate molecule for the treatment of conditions 
of compromised vascular health, such as peripheral vascular disease (PVD). 
Neovascularization involves several steps: endothelial proliferation that generates 
nascent vascular buds, directional migration of vascular buds that follows chemotactic 
growth factor gradients, maturation of the nascent vessels and finally, pruning of non-
essential vessels [4].  Previous studies have suggested that VEGF is one of the most 
potent factors capable of stimulating these events [3; 5]; rapid systemic introduction of a 
solution containing rhVEGF165, however, can result in severe hypotensive shock [6; 7].  
While local injection of liquid formulations of rhVEGF165 may induce 
neovascularization, this outcome is transient [8; 9].  Controlled release of liquid 
rhVEGF165 to result in a constant low dose of the molecule by implanted osmotic pumps, 
however, was found to result in neovascularization and vascular perfusion in a rabbit 
model of partial limb ischemia [10]. 
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The presence, and thus detection, of rhVEGF165 in the systemic circulation after being 
released from a bioerodible sustained release delivery system is influenced by the 
capacity of VEGF to bind heparin structures of the extracellular matrix elements in the 
region proximal to the delivery system [11].  Studies have demonstrated that heparin-
binding interactions have significant impact on the pharmacokinetics, and thus potentially 
the pharmacodynamic properties, of rhVEGF165 [12]. The pharmacokinetics of 
rhVEGF165 have been found to be non-linear; rhVEGF165 must first saturate the heparin-
binding sites before rhVEGF165 may be measured in the systemic circulation [12], 
potentially complicating the ability of the researcher to understand the in vivo release 
characteristics of a bioerodible depot releasing rhVEGF165. We have previously examined 
the nature of these interactions and the fate of VEGF at the site of injection [13].  
To date, little clinical success has been achieved using VEGF for the therapeutic 
treatment of PVD [14].  Since the sustained presence of VEGF appear to be essential for 
nascent vessel formation and maturation [1; 15], efforts have been made to achieve a 
durable neovascularization outcome by using local, sustained delivery approaches.  
Polymer scaffolds containing VEGF and platelet-derived growth factor [16] have shown 
in vivo benefits for the formation of mature new blood vessels.  Scaffolds made of 
poly(ether)urethane-polydimethylsiloxane (PEtU-PDMS) semi-interpenetrating 
polymeric network (semi-IPN) and fibrin loaded with VEGF and basic fibroblast growth 
factor have also shown promising results [17]. Collagen scaffolds chemically conjugated 
with VEGF have also been described [18].  Similarly, scaffolds prepared using an 85:15 
ratio of PLGA to deliver rhVEGF165 [19] and porous sponges composed of PLGA 
containing absorb rhVEGF165 stimulate new vascular growth following implantation [20].  
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More recently, microspheres prepared from PLGA [21; 22; 23] as well as PLGA/alginate 
[24] have been described for the sustained delivery of VEGF.  Our interest has also been 
to identify an injectable format for the sustained delivery of rhVEGF165; we have 
examined the use of microspheres prepared with 50:50 ratio of PLGA to encapsulate 
rhVEGF165 in order to result in its sustained delivery at a local site following injection 
[25].  One potential concern with the use of PLGA microspheres, however, it their 
capacity to incite tissue responses [26; 27; 28], events that might compromise rhVEGF165 
fate and function. 
We have now extended those previous studies using 50:50 lactide/glycolide ratio of 
PLGA microspheres to locally deliver rhVEGF165 by comparing that delivery system 
with PLGA dissolved in a bio-compatible organic solvent, N-Methyl-2-pyrrolidone 
(NMP) to form a gel that after injection and solvent dispersion will form a single implant 
that solidifies.  While both methods provide a delivery system that can be injected 
selectively into sites of reduced vascular function, the gel-based system may have 
pharmaceutical advantages of preparation and handling.   
In order to adequately assess relevant outcomes for PVD therapy using these two 
formulation approaches, methods were established to not only define critical parameters 
associated with the delivery of biologically active rhVEGF165 from these formulations, 
but also to describe the actions of long-term locally delivered rhVEGF165 on vascular re-
modeling.  Vascular casting was identified as a means to visualize vascular architecture 
with a high degree of resolution, with minimal artifacts and in three dimensions that also 
allows for temporal assessment of pharmacodynamic responses [29; 30].  Indeed, this 
technique has been used to evaluate the effects of a single intramuscular (IM) injection of 
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liquid VEGF in an induced ischemic animal model [31].  We have correlated vascular 
casting information with routine histology, up-regulation of cell surface markers present 
on nascent endothelial cells, as well as in vitro and in vivo profiles of rhVEGF165 release 
from these formulations.  Overall, our data supports the use of either approach, either 
PLGA microspheres or a PLGA/NMP gel for the local delivery of rhVEGF165 by 
injection to sites of peripheral ischemia to achieve sustained release of this potent 
mitogen in a manner previously suggested to achieve durable benefits in the context of 
PVD.  
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MATERIALS AND METHODS 
Materials 
E. coli-derived rhVEGF165 homo-dimer was produced and purified at Genentech, Inc. (S. 
San Francisco, CA).  The protein was formulated in succinate buffer at pH 5.0 with 
trehalose and polysorbate 20, then spray-freeze dried to yield a free-flowing solid phase 
material.  Poly(D,L-lactide-co-glycolide acid) (PLGA) as a 50:50 lactide/glycolide ratio 
with free acid end groups (RG502H ) was purchased from Boehringer Ingelheim. N-
methyl pyrrolidone (NMP, Pharmasolve, USP grade) was purchased from ISP 
Technologies and combined with the 50:50 (w/w) lactide/glycolide PLGA as described 
previously [32].  Sprague-Dawley rats and nude CD-1 immune-compromised mice were 
obtained from Charles River (Hollister, CA). 
 
Methods 
rhVEGF165 microsphere preparation  
Microspheres ranging in size between 20-90 μm diameter with an average of ~30 μm 
were prepared as previously described [25].  In brief, spray freeze-dried rhVEGF165 
powder (prepared as described earlier) was added to a mixture of PLGA/ethyl acetate (1.7 
g/ml) for 9% protein loading.  The solid phase protein was suspended in the liquid phase 
by homogenization and the suspension sprayed into a frozen bed of ethanol, subsequently 
warmed for 48 hours to 70
o
C to remove the ethyl acetate from the microspheres.  After 
filtration to remove the ethanol, microspheres were dried for 72 hours under nitrogen at 
5
o
C.  rhVEGF165 loading levels were verified by protein analysis [25].   
PLGA:NMP gel preparation 
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The gel was prepared by adding equal masses of PLGA and NMP to a sterile, capped 
glass vial and stirred overnight at room temperature to dissolve the polymer.  Gel was 
added by positive displacement pipette to pre-weighed spray freeze-dried rhVEGF165, 
prepared as described earlier [25] in differing masses to provide doses of 3.6 mg/kg, 0.72 
mg/kg and 0.36 mg/kg in the same dose volume.  Mixtures of spray freeze-dried 
rhVEGF165 and PLGA:NMP gel were made by homogenization at 8,000 RPM for two 
minutes with a VirTis Cyclone homogenizer (Gardiner, NY, USA).  
In vitro release studies 
In vitro release studies were performed at 37
o
C in a release media containing 10 mM 
histidine, 140 mM NaCl, 0.02% polysorbate 20 and 0.02% NaN3 at pH 7.0 with buffer 
replacement at sampling times.  The PLGA microsphere formulation contained 10 
mg/mL rhVEGF165, 1 mg/mL trehalose, 0.01% polysorbate 20, and 5 mM succinate at pH 
5.0. The NMP:PLGA (50:50 w/w) formulation contained 10 mg/mL rhVEGF165, 10 
mg/mL trehalose, 0.03% polysorbate 80, and 10 mM histidine at pH 6.0. The activity of 
released rhVEGF165 was assessed using an enzyme-linked immunosorbant assay (ELISA) 
assay format to assess VEGF receptor (KDR) binding [25].  As a surrogate assay for 
potency, this assay used a KDR-IgG chimera construct to demonstrate that rhVEGF165 
binding to its receptor remained intact.  Previous studies showed that rhVEGF165 
characterized as potent in this assay correlated with rhVEGF165 in a dimeric state (shown 
by size exclusion chromatography) and with the capability of heparin binding (shown by 
affinity chromatography) [25].   
In vivo studies  
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All in vivo experiments were carried out with local Institutional Animal Care and Use 
Committee (IACUC) approval in accordance with the institution’s ethical guidelines.  
In vivo pharmacokinetic studies 
As VEGF receptors are present on a variety of circulating white blood cells, in particular 
platelets [4], systemic time-concentration profiles were established by analysis of plasma 
rather than serum.  In order to examine in vivo rhVEGF165 release and presence in the 
systemic circulation, formulations containing the highest rhVEGF165 concentration, 3.6 
mg/kg, were used.  At this higher dose, the amount of rhVEGF165 released by each depot 
would overwhelm local capture through heparin binding events in the tissues and allow 
earlier detection in plasma over time.  Normal female Sprague-Dawley rats (200-250 g) 
were injected in the hind limb gastrocnemius muscle.  Rats were used for this aspect of 
the study rather than mice so that serial blood samples might be taken.  Plasma was 
harvested from whole blood samples taken over a seven-day period.  The study was 
terminated at seven days as prior investigations (data not shown) have shown the 
production of antibodies to this foreign (human) protein by one week to ten days after 
dosing.  Plasma concentrations of human RHVEGF165 were quantified using a dual 
monoclonal antibody-based ELISA format that had a limit of detection in plasma of 1 
pg/mL [12].  
In vivo dose administration 
These studies were designed to assess durable responses to rhVEGF165 administered in a 
sustained manner.  Female nude CD-1 mice (20-25 g) were used as the animal model 
because they lack the ability to raise potent immunity to a non-self protein.  Mice were 
injected in the gastrocnemius muscle with rhVEGF165-containing or control preparations 
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of microsphere or gel formulations.  rhVEGF165 loaded microspheres or PLGA:NMP 
gels, designed to deliver rhVEGF165 in doses of 3.6, 0.72, or 0.36 mg RHVEGF165/kg, 
were injected using a 23-gauge needle.  Additionally, ethylene-oxide sterilized 
fluorescently labeled polystyrene divinylbenzene beads (nominal diameter of 30 μm, 
Duke Scientific, Palo Alto CA) were added to each formulation just prior to injection.  
Unlike the PLGA microspheres, these marker beads did not dissolve during the KOH 
maceration step (see below) and remained in the tissues.  The fluorescent nature of these 
marker beads provided a method to assess the tissue distribution of a formulation many 
days after injection. The consistent diameter of these marker beads were used as a 
microscopic sizing standard when examining vascular casts by SEM.  Animals were 
sacrificed on day 3, 7, 14, 21, 28 and between 60 and 75 days after a single dosing with 
one of the placebo or active sustained release formulations. 
 
Vascular casting 
On the day of sacrifice, heparinized mice were perfused through the descending aorta 
with phosphate-buffered saline (PBS) under anesthesia.  After the blood was exchanged 
with PBS as completely as possible, the vasculature was perfused with a low-viscosity 
resin, Mercox acrylic casting material, that consists of a resin (Ladd Research, Williston, 
VT, USA), to which benzoyl peroxide was added as a catalyst to polymerize the perfused 
polymer in situ at ambient temperature.  Both hind limbs were excised after curing for 
four hours, the skin removed and the muscle tissue of the leg macerated by serial 
digestions with 7% KOH so that only bone and resin casts remained.  Tissue-denuded 
vascular casts were rinsed, submerged in distilled water, frozen and lyophilized to 
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maintain the three dimensional structure of the vascular casts.  The resulting casts were 
sputter-coated with gold-palladium and viewed with a Philips XL30 environmental 
scanning electron microscope.   
Vasculature casts of rhVEGF165-dosed legs were compared to vasculature casts of untreated 
contra-lateral legs to account for the potential for systemic exposure as well as localized 
administration.  Because systemic exposure cannot be ruled out and the effect of the delivery 
system itself might have an effect on the vasculature, control mice were dosed with placebo 
microspheres and gel to compare the effect of the delivery platform itself.  
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RESULTS  
In vitro release characteristics of rhVEGF165 from gel and microsphere formulations are 
different. 
Cumulative in vitro release profiles for similar concentrations of rhVEGF165 formulated 
in either PLGA microspheres or PLGA:NMP gel for a six-day period are shown in Figure 
1.  The cumulative release profile for rhVEGF165-loaded microspheres demonstrated an 
initial rapid release, followed by a slower release rate.  rhVEGF165 release from similarly 
prepared PLGA microspheres was determined previously and shown to be complete 
between 25 and 30 days in the same in vitro release test system [25]  In contrast, the 
PLGA:NMP gel formulation tested under the same in vitro release test conditions 
released rhVEGF165 at an extremely slow rate over the same duration.  These differences 
in release profiles are consistent with these two formulation matrices having different 
diffusion paths and degradation mechanisms [25; 32].  
In vivo release characteristics of gel and microsphere formulations are similar. 
In contrast to in vitro release studies, peak plasma concentrations and total areas under 
the curve of rhVEGF165 following IM injection in normal rats were similar for the 
sustained delivery formulations prepared using PLGA microspheres and PLGA:NMP gel 
(Fig. 2).  One important difference was observed between these two formulations 
however.  While both formulations show sustained plasma rhVEGF165 concentrations 
over 7 days, the plasma concentration versus time profiles for rhVEGF165-containing 
PLGA microspheres were biphasic whereas the rhVEGF165-PLGA:NMP gel formulations 
demonstrated a profile with a sustained rise and subsequent fall.  Plasma concentration- 
time profiles observed in these studies using PLGA microspheres were considered typical 
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for this type of formulation: an initial burst resulting in high rhVEGF165 plasma levels 
within the first six hours post dosing, followed by a second peak that was reached a 
maximum at day 4.  Initial peak plasma concentrations of rhVEGF165 were likely due to 
release of readily available protein at the microsphere surface that entered the circulation 
after saturating tissue (heparin-like) binding sites at the injection site.  The second 
observed rhVEGF165 peak, occurring 48 hr after administration, was presumed to be due 
to rhVEGF165 that diffused from the microsphere core and was released by bulk erosion 
of the polymer matrix.  
Plasma concentration-time profiles obtained using normal rats dosed with rhVEGF165 
loaded PLGA:NMP gels showed a steady rise over the first 4 days that was maintained to 
day 7, the last day of blood sampling, although there was a transient decline observed in 
plasma rhVEGF165 levels measured on day 5.  This type of plasma rhVEGF165 profile 
suggested a slower initial release of rhVEGF165 from the PLGA:NMP gel matrix 
compared to the PLGA microspheres used in these studies.  Unlike the PLGA 
microspheres that produced high plasma levels within 6 hours of IM dosing, the slower 
rate of plasma level increase supports the hypothesis that rhVEGF165 is released from this 
gel matrix more slowly.  These plasma concentration-time profiles reflect systemic 
rhVEGF165 plasma concentrations resulting from the release from the formulation and the 
saturation of the local tissue binding, which serves as a physiological depot that is 
considered to be physiologically important for this heparin-binding protein.  Such tissue 
interactions have been previously described and visualized for rhVEGF165 at an IM site 
post injection [13]. 
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Analyses of vascular casts demonstrate localized markers of neovascular events. 
Vascular casts prepared from mouse hind limbs dosed with either PLGA microsphere or 
PLGA:NMP gel sustained-release formations of rhVEGF165 showed an increase in 
vascular density, diameter and permeability compared to the control-treated animals.  In 
general, these vascular casts showed vessel dilatation and a vascular organization 
strikingly dissimilar from the hierarchical branching pattern of vessels observed in 
specimens obtained from control-treated and untreated animals.  Marker beads were 
observed entrapped in the complex vascular plexus at locations that were consistent with 
the original site of injection.  The size of the mouse hind limb was sufficiently small to 
permit viewing the entire limb in the scanning electron microscope.  Although it is 
possible that marker beads could have migrated from the site of depot injection over the 
month-long time course of these studies, the marker beads were shown to faithfully 
define tissue bound and cell-associated fluorescent rhVEGF165 for a minimum of 12 hr 
post IM injection [13].  Additionally, these marker beads served as an internal sizing 
standard that allowed for an accurate correction of depth of field effects when analyzing 
scanning electron micrographs. 
A single IM injection of rhVEGF165-loaded microspheres produces long-term vascular 
effects  
Comparing scanning electron micrographs for time-matched control and rhVEGF165-
containing microsphere specimens, differences were readily apparent in hind-limb vasculature 
by three days post-treatment (Fig. 3).  Three days after dosing, extensive vessel enlargement 
and increased vascular permeability were readily observed.  Although it is possible that some of 
the effects observed by IM-injection of the rhVEGF165 microsphere formulation could have 
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been due to a potential inflammatory-foreign body response to the PLGA microspheres 
themselves [27], this was not the case.  A comparison of the vascular casts prepared from hind-
limbs treated with placebo microspheres (Fig. 3a) with those of tissues exposed to rhVEGF165-
loaded microspheres (Fig. 3b) showed a marked enlargement of vessel diameter and tissue 
effects that were directly associated with the delivery of rhVEGF165.   
Vessel enlargement was not likely to be due to vessel growth by three days, but rather to 
dilation of the vessel wall, a loosening of the basement membrane as well as enlarged 
fenestrations of the capillary wall and increased vascular leakiness or permeability.  Indeed, 
tissue analysis 4 days post-dosing with the rhVEGF165 microsphere formulations demonstrated 
profound swelling in the vicinity of the depot injection site, consistent with an increased 
vascular leakiness (Fig. 4).  Further, immunohistochemical assessment of macrophage 
recruitment (F4/80 antibody) and endothelial cell activation (up-regulation of CD31 expression) 
correlated strongly with known actions of rhVEGF165 at these depot injection sites (Fig. 4) and 
their established association with the ability of RHVEGF165 to induce edema [33].  By day 7 
post-dosing with rhVEGF165-containing PLGA microspheres, standard histological assessment 
and the distribution of smooth muscle actin (demonstrated by immunohistochemistry) could be 
used to verify residual edema and the beginnings of nascent vessel maturation at injection sites 
(Fig. 5).  It should be noted that a clinical outcome of hyper-permeable, dilated vasculature is 
hypotension, the dose limiting endpoint used in dose escalation for the VIVA trial that 
examined the safety and efficacy of rhVEGF165 following intra-coronary artery administration 
[7; 12].   
By day 28 post-dosing, rhVEGF165 release from the PLGA microsphere formulation 
used in these studies should have been completed.  Local vasculature of animals treated with 
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rhVEGF165 loaded microspheres, however, was still enlarged (Fig. 6).  Further, vascular cast 
morphology suggested that local vessels were still highly permeable as puddles or filamentous 
sheets of resin were frequently observed adjacent to these vessels.  Although such a finding 
would be consistent with the hypothesis that these vessels were (more) permeable to the resin 
that vessels in control preparations where this phenomenon was not observed, it is unclear 
whether this increased resin leakage was due to weakened vessel walls or the induction of 
incontinent vasculature.  In either case, rhVEGF165-microsphere injection sites demonstrated a 
mixture of vessels with immature morphological characteristics and nascent vasculature 
maturation at injection sites that could be defined by histochemical and immunohistochemical 
assessment (e.g. Figs. 4 & 5).   
rhVEGF165 delivered using PLGA:NMP gel can produce a dose-dependent vascular 
response 
PLGA:NMP gel formulations demonstrated a slower initial in vivo release of rhVEGF165 
than that observed for PLGA microsphere preparations; plasma rhVEGF165 levels following 
PLGA:NMP gel formulation injection peaked at 4 days while the PLGA microsphere 
formulation produce an initial plasma peak by 6 hr post IM injection.  Beyond that point, both 
gel and microsphere depot formulations appeared to produce similar sustained plasma levels of 
rhVEGF165.  These differences in concentration-time profiles did not appear to result in 
dramatic differences in the observed vasculature outcomes between these two sustained-
delivery formulation approaches for the same dose of rhVEGF165.  This lack of difference in 
vascular outcomes may have been due to the possibility that the high dose of rhVEGF165 being 
compared (3.6 mg/kg) may have resulted in an overwhelming local effect.  Comparison of 
vascular casts obtained over a 70 day period post-dosing of one of the three rhVEGF165 doses 
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tested using PLGA:NMP gel formulations, however, did demonstrate dose-dependent vascular 
responses with respect to initial edema, vascular diameter, and vessel leakiness (data not 
shown).   
Low dose rhVEGF165 (0.36 mg/kg) PLGA:NMP gel formulation injected IM produced 
extensive vascular effects by day 7 (Fig. 7a).  Some vessels were dilated and most demonstrated 
extensive tortuosity (Fig. 7a & 7b), a characteristic of nascent vasculature [34].  Vessel 
architecture at injection sites 7 days post-dosing with 0.72 mg/kg rhVEGF165 in PLGA:NMP gel 
showed vessel dilation similar to low-dose treated tissues (Fig. 8).  At day 7, IM injection sites 
receiving the high dose (3.6 mg/mg) PLGA:NMP gel formulation showed swollen, tortuous 
vasculature (Fig. 9a) with club-like endings for some vessels (Fig. 9b) consistent with 
neovascularization [34].  At day 29, vascular casts obtained from mice receiving the lowest dose 
(0.36 mg/kg) of rhVEGF165 in PLGA:NMP gel continued to demonstrate vascular changes 
consistent with activation of angiogenesis (Fig. 10).  Similar responses were observed for the 
mid (0.72 mg/kg) and high (3.6 mg/kg) doses of rhVEGF165 delivered in PLGA:NMP gel 
formulations at day 29 post-IM injection (data not shown).  Importantly, by day 70, vascular 
tortuosity was strongly correlated with rhVEGF165 dose (Fig. 11).  Although this dose-
dependent effect of rhVEGF165 in tortuosity was striking evident at day 70, this vascular 
parameter was not as evident at earlier times possibly due to the complicating actions of vessel 
dilation.  
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DISCUSSION  
One major finding of this study is that both rhVEGF165-containing PLGA microspheres 
and PLGA:NMP gel sustained-release dosage forms examined produced local vascular changes 
anticipated for this potent angiogenic factor.  Indices of local edema, vessel swelling and 
increased permeability correlated with increasing dose and temporal resolution. The sustained 
rhVEGF165 delivery systems described in this study resulted in increased vessel tortuosity that 
was maintained as long as 70 post-dosing.  This is particularly striking as this timeframe 
suggests that these morphological effects were observed more than one month after the PLGA 
microspheres or PLGA:NMP gel formulations would likely have ceased to deliver rhVEGF165.  
Further, similar effects were seen in animals in the lowest dose groups, whose rhVEGF165 
plasma concentrations would likely be below the limit of rhVEGF165 ELISA-based detection by 
two week after doing. These findings provide data that may be useful in the selection of a 
potential therapeutic drug dose and to determine the optimal duration for an efficacious dosing 
strategy for the treat of PVD with sustained-release formulations of rhVEGF165. 
A second important finding of these studies was the demonstration that a polymer-
solvent (PLGA:NMP) gel system could be used as a liquid carrier for the sustained release of 
biologically active rhVEGF165 following local injection.  Such an approach has several potential 
advantages over previous efforts to deliver VEGF using solid polymer microspheres or matrix 
systems.  In the present studies we used PLGA microspheres as a system to compare to 
PLGA:NMP gel delivery systems; a number of other solid systems have been described for the 
delivery of VEGF.  For example, implanted porous PLGA sponges (3x3x4 mm
3
) pre-soaked 
with 2.5-5 μg VEGF and lyophilized have been shown to produce new blood vessels after 2-3 
weeks [20].  Similarly, an 85:15 PLGA porous, mineralized scaffold was shown to release 
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biologically-active rhVEGF165 for up to 12 days [35] and facilitate neovascularization [36].  
Combining PLGA micropheres with alginate hydrogels containing VEGF has also been found 
to show promising pre-clinical results for the treatment of PVD following local injection [24].  
While these approaches successfully achieve the desired outcome of neovascularization, the 
PLGA:NMP system offers several advantages: flexibility of dose control through simple 
changes in drug/carrier ratio, admixing with no additional preparation steps, and simple 
injection compared to surgical implantation. While PLGA microspheres could have issues with 
needle-clogging due to particle settling, PLGA nanoparticles loaded with VEGF may reduce 
this issue, although these smaller particle exhibit a much faster payload release [22] compared 
to VEGF released from PLGA microspheres [23].  
Studies to define in vitro release characteristic of rhVEGF165 from these sustained 
release depot formations were performed under biologically-relevant pH and temperature 
conditions, in order to better simulate what may occur in vivo.  Cumulative in vitro rhVEGF165 
release from PLGA microspheres was consistent with and somewhat predictive of in vivo 
plasma profiles obtained in rats following IM injection.  This was not the case, however, for 
studies using the PLGA: NMP gel formulation.  While this system worked well as a sustained-
delivery depot for rhVEGF165 in vivo, there was very little detectable rhVEGF165 release in 
vitro, even though the amount of rhVEGF165 to be released was well within assay limits for the 
drug loading levels anticipated for these release studies.  Although not confirmed 
experimentally, it is thought that the in vitro cumulative release assay used for these studies did 
not contain critical factors/parameters present in vivo for the gel system to function properly as a 
releasing vehicle for rhVEGF165.  It is likely that the hydrophobic NMP solvent used to prepare 
the PLGA gel could not efficiently diffuse from the gel in vitro due to the extremely low 
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aqueous solubility of this solvent and the lack of serum proteins containing hydrophobic 
binding pockets.  In the presence of serum/tissue factors that could absorb this hydrophobic 
solvent it is presumed that NMP would be cleared efficiently from the depot site to allow the gel 
matrix to set up as a platform for rhVEGF165 release in vivo.  
Plasma concentration-time profiles of rhVEGF165 provide only one aspect of the 
complicated, multi-compartment pharmacokinetic parameters of this potent angiogenic factor.  
rhVEGF165 released from a drug-loaded depot into the tissue surrounding the injection site can 
bind to extracellular matrix elements through its heparin-binding domain [12; 13].  As 
rhVEGF165 interacts with cell-surface receptors at the injection site, the protein can be 
internalized by these cells.  Since rhVEGF165 also acts as a chemotactic molecule, the high local 
rhVEGF165 concentration gradient draws cells that express VEGF receptors on their surface 
(such as monocytes) to the injection site [13] which further increases the potential number of 
local rhVEGF165 binding sites over time.  Such associations could act to sequester low levels of 
rhVEGF165 at the injection site until local concentrations are sufficiently high to overwhelm this 
local binding compartment and spill over into the systemic (blood) compartment, resulting in a 
complex non-linear systemic concentration-time profile [12].  Once in the systemic circulation, 
rhVEGF165 would be sequestered by platelets in a manner that further acts to regulate its actions 
[37].  
Despite all the drawbacks and caveats of relying upon plasma concentration-time profile 
assessments for rhVEGF165, this information can be used to compare some performance 
parameters for sustained delivery formulations.  Indeed, that the high dose (3.6 mg/kg) PLGA: 
NMP gel and PLGA microsphere preparations produced comparable plasma levels of 
biologically-active (as defined by the KDR receptor-binding ELISA) rhVEGF165 and also 
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produced similar phamacodynamic responses at IM sites supports the possible use of plasma 
concentrations as a useful assessment tool.  A more valuable pharmacokinetic assessment for a 
sustained rhVEGF165 delivery, however, would be to monitor biologically-active rhVEGF165 at 
the depot site for the time course of the study.  Indeed, persistent local levels of rhVEGF165 that 
are too low to be measured in the systemic circulation by the KDR binding ELISA could be 
sufficient to elicit and sustain a desired angiogenic response.  Although some progress has been 
made toward assessing the biological activity of rhVEGF165 at an injection site over a 12 hr time 
frame [13], it is unlikely that current techniques could be sufficiently sensitive to monitor local 
rhVEGF165 concentrations beyond the initial phase of depot protein release due to the associated 
complexities of extracellular matrix and receptor binding.   
In the absence of pharmacokinetic data at the depot site, pharmacodynamic parameters 
become extremely valuable for comparing the performance of different sustained delivery 
formulations of rhVEGF165.  This is particularly important in light of studies suggesting PVD 
may be due to reduced responsiveness to neovascularization that can be overcome by local 
VEGF delivery [38].  In the present studies, we analyzed vascular casts by scanning electron 
microscopy (SEM) to evaluate the extent and persistence of rhVEGF165 actions.  This method 
has probably the highest resolution of any current technique for the pharmacodynamic 
assessment of vascular response to an angiogenic factor such as rhVEGF165.  While others have 
used SEM and transmission electron microscopy to assess the angiogenic potential of VEGF-
polymer matrices [20], SEM analysis of vascular casts permits visual observation of a number 
of vessel parameters such as diameter, permeability, branching, tortuosity, etc [33].  We also 
found that the use of 30 nm-diameter fluorescent latex beads as a co-injected element to not 
only assist in the localization of injection sites (even weeks after administration) but also to 
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provide an internal size standard to allow easy calibration throughout the entire depth of an 
SEM micrograph.  One drawback of vascular casting, however, is that this is a terminal 
procedure, allowing for the capture of only one time point and does not allow for assessment 
over time in the same animal.  Capillary density changes over time can be examined by 
videomicroscopy and vasodilation can be assessed by laser Doppler flowmetry [39].  
Ultrasound biomicroscopy or micro-ultrasound imaging and micro-computed tomography 
analysis have also been used to assess temporal changes in functional blood flow [40].  Thus, 
there are vital methods that can be used to correlate with terminal microscopy methods such as 
vascular casts analyzed by SEM.  
Although functional blood flow parameters were not correlated with the vascular casting 
data obtained in the current study, several other parameters associated with vascular function 
and angiogenesis were evaluated.  Immunohistochemistry using antibodies to VEGF and CD34 
have been used to correlate microvessel density with non-invasive measurements of vascular 
function [41].  We correlated vascular cast information with vessel density using CD31 
(PECAM1) and smooth muscle actin expression, as well as F4/80 expression to monitor 
monocyte/macrophage infiltration, and hematoxylin/eosin staining to assess local edema.  
Although all of these methods are prone to some level of artifact and uncertainty, co-injected 30 
nm-diameter fluorescent latex beads were used to verify depot injection sites and ensure that 
correct tissue sites were analyzed by these various techniques.  Overall, the data presented in 
this report supports the contention that a sustained, local delivery of rhVEGF165 can be achieved 
from a single injection using formulations of either PLGA microspheres or a gel composed of 
PLGA/NMP.  While both of these approaches provide an method to incite neovascularization 
using sustained delivery systems that can be injected rather than surgically implanted, flexibility 
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of the PLGA:NMP system may be particularly useful for dose-ranging studies in clinical 
settings.  Obviously, further evaluation in relevant pre-clinical models would be important to 
support the potential of such formulations for the clinical treatment of PVD.   
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FIGURES 
Figure 1.  Percent cumulative in vitro release rates of rhVEGF from PLGA microspheres (open 
circles) and PLGA: NMP gel (solid circles).  Microspheres had 8.9% w/w loading of rhVEGF 
and the PLGA: NMP gel had 0.65% w/w loading of rhVEGF.  
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Figure 2.  Pharmacokinetic profiles of plasma rhVEGF concentrations over time of normal rats 
following intramuscular dosing with 3.6 mg/kg rhVEGF loaded PLGA microspheres (circles) 
and 3.6 mg/kg rhVEGF in PLGA:NMP gel (triangles).  
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Figure 3.  Vascular casts of intramuscular injection sites three days after dosing with control 
microspheres (a) or 3.6 mg/kg rhVEGF loaded-microsphere (b).  Note vessel dilation in 
response to rhVEGF exposure.  Co-injected polystyrene divinylbenzene (non-dissolving) beads 
(30 μm) are denoted by arrows.  
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Figure 4.  Distribution of macrophage infiltration and endothelial cell activation as a result of 
local, sustained delivery of rhVEGF.  Serial tissue sections obtained from an intramuscular 
injection site of 3.6 mg/kg rhVEGF in PLGA microspheres four days post-dose were labeled 
with (a) the F4/80 antibody specific for mouse macrophages or (b) the cell surface marker CD31 
associated with endothelial cell proliferation.  The injection site is indicated by an arrow.  
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Figure 5.  Induction of local edema and nascent vasculature following local, sustained delivery 
of rhVEGF.  Tissues sections obtained from an intramuscular injection site of 3.6 mg/kg 
rhVEGF in PLGA microspheres seven days post-dose were (a) stained with hematoxylin and 
eosin to assess local edema and cellular infiltration or (b) labeled with an antibody specific for 
mouse smooth muscle actin to delineate the presence of nascent vasculature.  
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Figure 6.  Vascular casts of intramuscular injection site 28 days after dosing IM with 3.6 mg/kg 
rhVEGF loaded microspheres.  Note increased leakage of injected resin.  Co-injected 
polystyrene divinylbenzene beads (30 μm) are denoted by arrows. 
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Figure 7.  Vascular casts of intramuscular injection site 7 days after dosing with 0.36 mg/kg 
rhVEGF in PLGA:NMP gel shown at (a) lower and (b) higher magnifications highlighting 
vessel tortuosity.  Co-injected polystyrene divinylbenzene beads (30 μm) are denoted by arrows. 
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Figure 8.  Vascular casts of intramuscular injection site 7 days after dosing with 0.72 mg/kg 
rhVEGF in PLGA:NMP gel.  Co-injected polystyrene divinylbenzene beads (30 μm) are 
denoted by arrows. 
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Figure 9.  Vascular casts of intramuscular injection site 7 days after dosing with 3.6 mg/kg 
rhVEGF in PLGA:NMP gel.  Examples of (a) vascular leakiness and vessel dilation as well as 
(b) club-like vessel endings showing individual endothelial cell organization at sites of nascent 
vessel formation are shown.  Note Co-injected polystyrene divinylbenzene beads (30 μm) are 
denoted by arrows. 
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Figure 10.  Vascular casts of intramuscular injection site 29 days after dosing with 0.36 mg/kg 
rhVEGF in PLGA:NMP gel.  Co-injected polystyrene divinylbenzene beads (30 μm) are 
denoted by arrows. 
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Figure 11.  Vascular casts of intramuscular injection site 70 days after dosing with 3.6 mg/kg 
rhVEGF in PLGA:NMP gel showing examples of the tortuous, but organized, nature of the 
vascular bed at (a) lower and (b) higher magnifications.  
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